This inventor holds 1 USPTO granted patent. Top assignee: Leibniz-Institut Fur Analytische Wissenschaften - Isas - E.v.. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Hideo A Baba: Innovator in Biomarkers for Cholangiocellular Carcinoma
Introduction
Hideo A Baba is a prominent inventor based in Essen, Germany. He has made significant contributions to the field of medical diagnostics, particularly in the identification of biomarkers for cholangiocellular carcinoma (CCC). His innovative work has the potential to enhance the diagnosis, surveillance, and treatment of this challenging cancer.
Latest Patents
Hideo A Baba holds a patent related to biomarkers for cholangiocellular carcinoma. The invention focuses on a method for identifying specific marker proteins that serve as biomarkers for CCC. This method not only identifies the biomarkers but also outlines their use in diagnosis, surveillance, and treatment. Additionally, the invention includes a diagnostic device that incorporates these biomarkers and a screening assay designed to identify novel pharmaceutical compounds for the treatment of CCC. He has 1 patent to his name.
Career Highlights
Hideo A Baba is affiliated with the Leibniz Institute for Analytical Sciences (ISAS) in Germany. His work at this esteemed research institution has allowed him to collaborate with other experts in the field, further advancing the understanding and treatment of cholangiocellular carcinoma.
Collaborations
Hideo A Baba has worked alongside notable colleagues such as Thilo Bracht and Dominik Megger. Their collaborative efforts have contributed to the development of innovative diagnostic methods and treatments for CCC.
Conclusion
Hideo A Baba's contributions to the field of biomarkers for cholangiocellular carcinoma represent a significant advancement in medical diagnostics. His innovative methods and collaborative work continue to pave the way for improved diagnosis and treatment options for patients suffering from this disease.